论文部分内容阅读
为提高对重型再生障碍性贫血（ＳＡＡ）治疗的疗效，１９９０年以来，在雄激素常规联合方案基础上加用环孢霉素Ａ（ＣｓＡ）或大剂量甲基泼尼龙（ＨＤＭＰ）治疗成人ＳＡＡ２２例，并以单用雄激素常规联合方案的１１例为对照组，进行疗效随访观察。结果总有效率ＣｓＡ组为７１．４％（１０／１４），ＨＤＭＰ组为６２．５％（５／８），对照组为１８．２％（２／１１）。显示ＣｓＡ组和ＨＤＭＰ组的疗效均优于对照组（Ｐ＜０．０１和Ｐ＜０．０５）。ＣｓＡ组和ＨＤＭＰ组均未出现严重毒副反应。个别患者ＣｓＡ须维持疗程长达３年，提示对ＣｓＡ维持疗程与剂量的个体化应予一定的注意。认为在雄激素常规联合方案基础上加用ＣｓＡ或ＨＤＭＰ治疗ＳＡＡ，是较为有效、安全和简便的方法。
To improve the efficacy of treatment of patients with severe aplastic anemia (SAA), adult SAA22 was added to cyclophosphamide (CsA) or high-dose methylprednisolone (HDMP) in addition to conventional androgenic regimens since 1990 Cases, and the combined use of androgen routine eleven cases as a control group, the efficacy of follow-up observation. Results The total effective rate was 71.4% (10/14) in CsA group, 62.5% (5/8) in HDMP group and 18.2% (2/11) in control group. The efficacy of CsA and HDMP groups was better than that of the control group (P <0.01 and P <0.05). No serious side effects were found in CsA and HDMP groups. Individual patients with CsA to maintain the course of up to 3 years, suggesting that individual treatment of CsA maintenance dose and dose should be given some attention. It is considered that adding CsA or HDMP to SAA on the basis of androgen routine regimen is an effective, safe and easy method.